Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Amgen

Clinicaltrial registered2 Nov 2026

Amgen

2 Nov 2026: Trial registered · Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA). Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
2 Nov 2026
Title
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Conditions
Obesity, Overweight
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
United States
Country
United States
Reference
NCT07908316
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Amgen

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Amgen in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.